These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1559000)

  • 1. Serpentine supravenous hyperpigmentation induced by the nitrosourea fotemustine.
    Claudy AL; Lévigne V; Boucheron S
    Dermatology; 1992; 184(1):70-2. PubMed ID: 1559000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A probable mechanism for hyperpigmentation by fotemustine.
    Schallreuter KU; Ring J
    Dermatology; 1992; 185(1):76-7. PubMed ID: 1638080
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
    Mangiacavalli S; Pica G; Varettoni M; Lazzarino M; Corso A
    Eur J Haematol; 2009 Mar; 82(3):240-1. PubMed ID: 19018860
    [No Abstract]   [Full Text] [Related]  

  • 4. [Fotemustine: muphoran].
    Avril MF
    Ann Dermatol Venereol; 2007 Dec; 134(12):997-1000. PubMed ID: 18166925
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma.
    Le Chevalier T; Zabbe C; Gouva S; Cerrina ML; Quoix E; Riviere A; Berthaud P; Prache C; Berille J
    Eur J Cancer Clin Oncol; 1989 Nov; 25(11):1651-2. PubMed ID: 2687005
    [No Abstract]   [Full Text] [Related]  

  • 6. Neurological toxicity during metastatic melanoma treatment with fotemustine.
    Khalil Z; Pageot N; Carlander B; Guillot B
    Melanoma Res; 2005 Dec; 15(6):563-4. PubMed ID: 16314745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
    Gill S; Shapiro J; Westerman D; Prince HM
    J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
    [No Abstract]   [Full Text] [Related]  

  • 8. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
    Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group.
    Kerbrat P; Somers R; Verweij J; Crowther D; Tursz T; Santoro A; Steward WP; Lentz MA; van Glabbeke M; Mouridsen HT
    Eur J Cancer; 1992; 29A(1):143-4. PubMed ID: 1445732
    [No Abstract]   [Full Text] [Related]  

  • 10. Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group).
    Rougier P; van Pottelsberghe C; Kok T; Paillot B; Wagener T; De Greve J; Fabri MC; Gerard B; Van Glabbeke M; Bleiberg H
    Eur J Cancer; 1996 Jul; 32A(8):1432-3. PubMed ID: 8869111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
    Jacquillat C; Khayat D; Banzet P; Weil M; Avril MF; Fumoleau P; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
    Cancer Chemother Pharmacol; 1990; 25(4):263-6. PubMed ID: 2403853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
    Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
    Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer.
    Rudd R; Allen R; Berille J; Spiro SG; Trask C; Souhami RL
    Cancer Chemother Pharmacol; 1994; 34(5):444-6. PubMed ID: 8070014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
    Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
    Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal effects of S10036 in man.
    Deray G; Khayat D; Jacquiaud C; Bizzari JP; Bourbouze R; Musset L; Jaudon MC; Baumelou B; Jacquillat C; Jacobs C
    Cancer Chemother Pharmacol; 1990; 26(6):467-8. PubMed ID: 2225319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fotemustine for the treatment of melanoma.
    Quéreux G; Dréno B
    Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
    Beauchesne PD; Taillandier L; Bernier V; Carnin C
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
    J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of fotemustine in pediatric patients with refractory brain tumors.
    Hargrave DR; Bouffet E; Gammon J; Tariq N; Grant RM; Baruchel S
    Cancer; 2002 Sep; 95(6):1294-301. PubMed ID: 12216098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.